NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers

被引：0

作者：

Chrissie E. B. Ong

Amanda L. Patchett

Jocelyn M. Darby

Jinying Chen

Guei-Sheung Liu

A. Bruce Lyons

Gregory M. Woods

Andrew S. Flies

机构：

[1] Menzies Institute for Medical Research,Department of Ophthalmology

[2] College of Health and Medicine,Ophthalmology, Department of Surgery

[3] University of Tasmania,Tasmanian School of Medicine, College of Health and Medicine

[4] The First Affiliated Hospital of Jinan University,undefined

[5] University of Melbourne,undefined

[6] University of Tasmania,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷

关键词：

Transmissible cancer; Devil facial tumor; Allograft; MHC-I; NLRC5; Immune evasion;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1973 / 1991

页数：18

共 50 条

[41] Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune response
Tan, Lianmei
Yin, Tao
Xiang, Handan
Wang, Liuyang
Mudgal, Poorva
Chen, Junying
Ding, Yi
Wang, Guoping
Lim, Bryan Jian Wei
Huang, Yuqi
Huang, De
Liang, Yaosi
Alexander, Peter B.
Xiang, Kun
Wang, Ergang
Yan, Chengsong
Ma, Zhehao
Tan, Minjia
Li, Qi-Jing
Wang, Xiao-Fan
NATURE COMMUNICATIONS, 2024, 15 (01)
[42] RADIATION MODULATES THE PEPTIDE REPERTOIRE, ENHANCING MHC CLASS I EXPRESSION AND IMPROVING ANTI-TUMOR IMMUNO-THERAPY
Neefjes, J.
Qiao, X.
Pang, B.
RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S168 - S168
[43] Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10
Mowat, Courtney
Mosley, Shayla R.
Namdar, Afshin
Schiller, Daniel
Baker, Kristi
JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (09):
[44] Cutaneous over-expression of RANKL up-regulates MHC class I-mediated anti-viral immunity
Klenner, L.
Hafezi, W.
Kupas, V.
Lorentzen, E.
Luger, T. A.
Kuehn, J.
Beissert, S.
Loser, K.
EXPERIMENTAL DERMATOLOGY, 2012, 21 (03) : e25 - e25
[45] MHC class I-restricted tumor epitope specific TCR engineered CD4+ T cells function as helper and cytolytic effector cells in anti-tumor immunity
Chhabra, Arvind
Yang, Lili
Wang, Pin
Chakraborty, Nitya G.
Das, Raja
Ribas, Antoni
Kohn, Donald
Baltimore, David
Economou, James
Mukherji, Bijay
JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 899 - 899
[46] MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3
Weixin Liu
Ruibao Liu
Ronghui Yuan
Xing Wang
Molecular Biotechnology, 2021, 63 : 1268 - 1279
[47] MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3
Liu, Weixin
Liu, Ruibao
Yuan, Ronghui
Wang, Xing
MOLECULAR BIOTECHNOLOGY, 2021, 63 (12) : 1268 - 1279
[48] Irreversible electroporation combined with PD-L1/IL-6 dual blockade promotes anti-tumor immunity via cDC2/CD4+T cell axis in MHC-I deficient pancreatic cancer
Wu, Zhuozhuo
Shan, Qungang
Jiang, Yuyue
Huang, Wei
Wang, Ziyin
Zhuang, Yaping
Liu, Jingjing
Li, Tiankuan
Yang, Ziyu
Li, Chaojie
Wei, Tao
Wen, Chenlei
Cui, Wenguo
Qiu, Zilong
Liu, Xiaoyu
Wang, Zhongmin
CANCER LETTERS, 2025, 617
[49] Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4/NAIP5 activation and induces TLR5-independent anti-tumor immunity
Kuo-Hsing Lin
Li-Sheng Chang
Chun-Yuan Tian
Yi-Chen Yeh
Yu-Jie Chen
Tsung-Hsien Chuang
Shih-Jen Liu
Chih-Hsiang Leng
Scientific Reports, 6
[50] Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4/NAIP5 activation and induces TLR5-independent anti-tumor immunity
Lin, Kuo-Hsing
Chang, Li-Sheng
Tian, Chun-Yuan
Yeh, Yi-Chen
Chen, Yu-Jie
Chuang, Tsung-Hsien
Liu, Shih-Jen
Leng, Chih-Hsiang
SCIENTIFIC REPORTS, 2016, 6

← 1 2 3 4 5 →